Galecto Inc (GLTO) Stock Price, Quote & News

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 52 10

Website: galecto.com

Address:

Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark

can8232 Nov. 13 at 11:43 AM

$GLTO בוא נהמר היום על 28$ מינימום!!!!!!!!!

1 · Reply

SpartanVI Nov. 13 at 9:28 AM

$GLTO $HOUR $KIDZ $MSGM $WLDS Kidz Getting started 🔥👀

0 · Reply

Bigwinner75 Nov. 13 at 9:25 AM

$GLTO how is that. If you like this stock so much. You can hold on to it. You can be a long time shareholder. Lol

0 · Reply

SpartanVI Nov. 13 at 9:23 AM

$KIDZ $KIDZ $OPEN $BYND $GLTO $SOND Crazy potential KIDZ Bottom play

1 · Reply

SpartanVI Nov. 13 at 9:16 AM

$GLTO $HOUR $KIDZ $MSGM $WLDS Kidz nice potential Golden Sac purchase

0 · Reply

Bigwinner75 Nov. 13 at 9:15 AM

$GLTO whoever buy this garbage , you have a chance to win 10%. But you have a risk to lose 90%.

0 · Reply

Bigwinner75 Nov. 13 at 9:12 AM

$GLTO also. They just did a reverse split a year old to stay in the market. What? They think they are Nvidia or something now ? Are you joking

0 · Reply

Bigwinner75 Nov. 13 at 9:09 AM

$GLTO this piece of garbage is losing money every quarter. Burn cash 1.3 million every 3 month. Hardly any cash. Yes. It gave me lot of reason to short at 19. I will even short this at 9 dollars

0 · Reply

Bigwinner75 Nov. 13 at 9:08 AM

$GLTO you are absolutely right. Who will buy this piece garage at 27 dollars ?

0 · Reply

BearTamerTrading Nov. 13 at 7:18 AM

🚀 Premarket Power Plays — Bear Tamer Trading Community Wins 🔥 Part 2/2 Here are the catalysts that sparked today’s moves: 🔥 $BODI — Reported first quarterly net profit since IPO, gross margins jumped to ~74%, strong digital-subscription pivot. 🔥 $CMCT — Announced sale of lending division (~$44M deal), unlocking ~$31M net cash and refocusing on core real-estate assets. 🔥 $BW — Investor momentum from strategic turnaround toward AI-data-center infrastructure, hydrogen, and decarbonization projects. 🔥 $PRFX — Low-float biotech with attention on upcoming PRF-110 milestones and diversification into AI-driven solar analytics. 🔥 $GLTO — Clinical-stage biotech with upcoming IND milestone for GB3226 (oncology), drawing speculative interest. Members were already in position before the volume spike due to timely alerts 💪 If you missed it, watch the replay for proof — testimonials are in the comments ⬇️ 👉 https://www.youtube.com/live/aKG9DgeDqUo?si=9SdTH58Xrih4Rp6x

3 · Reply

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

MOVE

Nov 10, 2025, 11:47 AM EST - 2 days ago

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Nov 10, 2025, 7:00 AM EST - 2 days ago

Galecto Announces Acquisition of Damora Therapeutics

Nov 6, 2025, 4:30 PM EST - 6 days ago

Galecto Reports Third Quarter 2025 Operating and Financial Results

Oct 7, 2025, 1:05 PM EDT - 5 weeks ago

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 10:27 AM EDT - 5 weeks ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Aug 5, 2025, 4:15 PM EDT - 3 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 6 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Mar 19, 2025, 4:45 PM EDT - 8 months ago

Galecto Reports Full-Year 2024 Financial Results

Feb 6, 2025, 8:00 AM EST - 9 months ago

Galecto to Participate in Upcoming Investor Conferences

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 2, 2023, 4:05 PM EST - 2 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 1, 2023, 8:00 AM EST - 3 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Mar 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Feb 17, 2022, 5:00 PM EST - 4 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

can8232 Nov. 13 at 11:43 AM

$GLTO בוא נהמר היום על 28$ מינימום!!!!!!!!!

1 · Reply

SpartanVI Nov. 13 at 9:28 AM

$GLTO $HOUR $KIDZ $MSGM $WLDS Kidz Getting started 🔥👀

0 · Reply

Bigwinner75 Nov. 13 at 9:25 AM

$GLTO how is that. If you like this stock so much. You can hold on to it. You can be a long time shareholder. Lol

0 · Reply

SpartanVI Nov. 13 at 9:23 AM

$KIDZ $KIDZ $OPEN $BYND $GLTO $SOND Crazy potential KIDZ Bottom play

1 · Reply

SpartanVI Nov. 13 at 9:16 AM

$GLTO $HOUR $KIDZ $MSGM $WLDS Kidz nice potential Golden Sac purchase

0 · Reply

Bigwinner75 Nov. 13 at 9:15 AM

$GLTO whoever buy this garbage , you have a chance to win 10%. But you have a risk to lose 90%.

0 · Reply

Bigwinner75 Nov. 13 at 9:12 AM

$GLTO also. They just did a reverse split a year old to stay in the market. What? They think they are Nvidia or something now ? Are you joking

0 · Reply

Bigwinner75 Nov. 13 at 9:09 AM

$GLTO this piece of garbage is losing money every quarter. Burn cash 1.3 million every 3 month. Hardly any cash. Yes. It gave me lot of reason to short at 19. I will even short this at 9 dollars

0 · Reply

Bigwinner75 Nov. 13 at 9:08 AM

$GLTO you are absolutely right. Who will buy this piece garage at 27 dollars ?

0 · Reply

BearTamerTrading Nov. 13 at 7:18 AM

3 · Reply

StockAlertzz Nov. 13 at 6:45 AM

$GLTO most shorts opened at 19 they stuck hoping to break even I suggest take the loss or cover over 27 soon in my opinion.. source trust me :)

0 · Reply

PaulLaurent Nov. 13 at 6:43 AM

🌅 4:00am EST Watchlist $NVVE – Japan unit secured the country’s first aggregation agreement for existing assets—steps toward monetizing V2G. Watch scope (sites/MW), revenue model, rollout timing, and utility follow-ons. $SGBX – AH runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests. $OPEN – Potential multi-day runner. Track borrow dynamics, housing headlines, and clean reclaims of prior HOD. $GLTO – Potential multi-day runner. Post-deal carry; favor VWAP holds and liquidity expansion. $LPTX – Potential multi-day runner. Rebrand/news momentum; look for higher-low structure and filings cadence. Tone: Catalyst carry and AH momentum lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.

0 · Reply

StockAlertzz Nov. 13 at 6:41 AM

$GLTO TODAY NEXT LEG UP ⬆️ BETTER COVER SOON SHORTS 🩳 THIS IS ur final chance ;)

0 · Reply

BennyBjammin Nov. 13 at 4:59 AM

$GLTO This is hilarious. I wasn't lying. It did retrace back to this zone, but only after hitting $33 first. However, once it hit that zone, it ran 30%+ from sub $21 to $28.

0 · Reply

Nova_Trades Nov. 13 at 4:52 AM

Thursday Watchlist — Pt. 8 $WLDS, $MSGM, $HOUR, $KIDZ, $GLTO watching for clean volume surges and breakout confirmation. 📊

0 · Reply

murphyraphael Nov. 13 at 4:14 AM

$GLTO $ASTS Buyers have gained a crushing advantage. https://stocktwits.com/murphyraphael

0 · Reply

NextRunnerTV Nov. 13 at 3:54 AM

Everyone is looking for the next $SPRB $GLTO low floater parabolic runner. Its most likely a stock like $TRUG $SGBX With massive short interest, and tiny floats.

0 · Reply

tainuibull Nov. 13 at 3:47 AM

$GLTO

0 · Reply

Stock_Catcher Nov. 13 at 2:49 AM

Monday $GLTO 400% Runner Tuesday $LFS Almost 1000% Runner Wednesday $LPTX 420% Runner , Let's see what I find tomorrow 👀🦢🤫see you in morning

1 · Reply

Stock_Catcher Nov. 13 at 2:06 AM

Money Thursday Watchlist Pt. 3 $GLTO $HOUR $KIDZ $MSGM $WLDS Tomorrow let's find more big runners📈

0 · Reply

Stock_Catcher Nov. 13 at 1:41 AM

New Video Out Just Now on Bullish Analysis on $OPEN $GLTO $PSTV $RR $NXXT and potential more ! https://www.youtube.com/watch?v=v6stDH_pZy4

0 · Reply

Joby099 Nov. 13 at 12:35 AM

$GLTO

0 · Reply

Market Cap	31.30M
Revenue (ttm)	0.00
Net Income (ttm)	-21.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,502,700
Avg Vol	4,431,012
Day's Range	N/A - N/A
Shares Out	1.33M
Stochastic %K	65%
Beta	1.45
Analysts	Hold
Price Target	$6.00